Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary EDAP Schedules Webcast and Conference Call for First Quarter 2013 Results
LYON, France , May 13, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today details relating to its first quarter 2013 results announcement, which will take place on Thursday, May 16, 2013 , before the opening of the market.
View HTML
Toggle Summary EDAP Outlines Significant Participation at 2013 American Urological Association Annual Meeting
Four scientific sessions highlighting HIFU outcomes for treatment of prostate cancer One AUA accepted poster presentation highlighting Sonolith lithotripter and its exclusive ultrasound Visio Track ® localization system EDAP attending the FDA Public Workshop on prostate cancer clinical trial design
View HTML
Toggle Summary EDAP Announces 23% First Quarter 2013 Revenue Growth
First quarter total revenue of approximately EUR 5.9 million ( USD 7.8 million ), up 23% year-over-year Ten lithotripsy devices sold in first quarter 2013 Received FDA acceptance for PMA filing on March 26, 2013 , for Ablatherm®-HIFU for treatment of low risk, localized prostate cancer LYON, France
View HTML
Toggle Summary EDAP Reports Fourth Quarter 2012 and Full Year Results
Highlights   Record fourth quarter 2012 revenue of EUR 9.5 million ( USD 12.3 million ), up 25.3% year-over-year Record full year revenue of EUR 26.1 million ( USD 33.6 million ), up 16.9% year-over-year Record lithotripsy sales in 2012 PMA for Ablatherm®-HIFU for treatment of low risk, localized
View HTML
Toggle Summary EDAP Receives U.S. FDA Filing Acceptance of Pre-Market Approval Application
Ablatherm(R)-HIFU PMA Application Proceeds to Substantive Review
View HTML
Toggle Summary EDAP Introduces Focal.One(R): A New Robotic HIFU Device for Focal Therapy of Prostate Cancer
Focal.One World Premiere at European Association of Urology Annual Congress
View HTML
Toggle Summary EDAP Schedules Webcast and Conference Call for Fourth Quarter and Full Year 2012 Results
LYON, France , March 12, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today details relating to its fourth quarter and full year 2012 results announcement, which will take place on Tuesday, April 2, 2013 , before the opening of the
View HTML
Toggle Summary EDAP Receives U.S. FDA Administrative Acceptance Review Notification for Ablatherm(R)-HIFU Pre-Market Approval Application
PMA for Treatment of Low Risk, Localized Prostate Cancer
View HTML
Toggle Summary EDAP's Ablatherm-HIFU Offers Reliable Therapy for Localized Prostate Cancer
Munich Study Concludes 15 Year Outcome Data May Warrant Closing of Investigational Phase for HIFU
View HTML
Toggle Summary EDAP's Ablatherm-HIFU Demonstrates Long-Term Efficacy and Safety Over Fourteen-Year Period
Longest Retrospective Study of HIFU Patients to Date Published Confirms Benefits of Treatment
View HTML